In November 2021, Arkansas enacted a law, known as Act 1103, that prohibited drugmakers from placing restrictions on 340B contract pharmacies and child sites. The Pharmaceutical Research and Manufacturers of America (PhRMA) immediately filed suit to block implementation of Act 1103, delaying enforcement of the law for nearly 2 years. However, on March 12, 2024, the U.S. Court of Appeals for the Eighth Circuit rejected PhRMA’s arguments and ruled Act 1103 is valid and enforceable. In the podcast, we talk about the implications of the ruling for the broader 340B program and covered entities nationwide.
Kyle Robb, PharmD is director of State Policy & Advocacy at ASHP. Kyle supports ASHP members and State Affiliates as they seek to advance the practice of pharmacy through engagement with state government.
Prior to working at ASHP, Kyle was a pharmacist at the University of Virginia Health System and a health policy fellow on the staff of the U.S. Senate Committee on Health, Education, Labor & Pensions. 
Tom Kraus, JD, (he/him) is vice president for government relations at ASHP. He is a graduate of University of Michigan (BS Biology), Georgetown University Law Center (Doctor of Law), and The Johns Hopkins University (MHS, Health Policy). Tom previously served as the chief of staff and associate commissioner for legislation at the U.S. Food and Drug Administration. He was also a senior policy advisor to Sen. Ted Kennedy and Sen. Tom Harkin on the Senate Health, Education, Labor and Pensions Committee, where he served as Deputy Staff Director for Health. 
